Anke Bio's Wholly-Owned Unit Suhao Yiming Gets NMPA Approval for Terlipressin Acetate API
Anke Bio's wholly-owned sub-subsidiary, Shanghai Suhao Yiming Pharmaceutical Co. , Ltd. , received on July 29 the Chemical API Marketing Application Approval Notice from the National Medical Products Administration for terlipressin acetate. The API will be used to produce terlipressin preparations, which are indicated for the treatment of gastrointestinal bleeding, genitourinary bleeding, postoperative bleeding, and hepatorenal syndrome.
Why this event matters
The event has a measured impact on 1 industry. The strongest current signal is positive for Pharmaceuticals, with intensity 40/100 and 70% confidence over a short term horizon.
Impact figures are analytical estimates that combine direction, intensity, confidence and event importance. They are not investment advice.